Angiotensin receptor-neprilysin inhibitor in patients with heart failure and chronic kidney disease
Despite significant advances in the management of heart failure with reduced ejection fraction (HFrEF), there remains an enormous health problem with high morbidity and mortality over the last few decades. The neprilysin inhibitor enhances the activity of natriuretic peptides, producing vasodilation...
Збережено в:
| Автори: | , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
The Korean Society of Nephrology
2021-12-01
|
| Серія: | Kidney Research and Clinical Practice |
| Предмети: | |
| Онлайн доступ: | http://www.krcp-ksn.org/upload/pdf/j-krcp-21-900.pdf |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|